Advertisement
Advertisement
VNRX
VolitionRx Limited
0.18
USDSponsored
-0.02
-7.80%
Nov 10, 15:54 UTC -5
Closed
After-Market
0.20
+0.01
+6.83%
VolitionRx Limited (VNRX) Earnings
VNRX Earnings Reports
Positive Surprise Ratio
VNRX beat 24 of 43 last estimates.
56%
Next Report
In 2 Days
Date of Next Report
Nov 12, 2026
Estimate for Q3 26 (Revenue/ EPS)
$720.63K
/-$0.35
Implied change from Q2 26 (Revenue/ EPS)
+81.06%
/-58.82%
Implied change from Q3 25 (Revenue/ EPS)
+14.88%
/-65.00%
VolitionRx Limited earnings per share and revenue
On Aug 13, 2026, VNRX reported earnings of -0.85 USD per share (EPS) for Q2 26, missing the estimate of -0.58 USD, resulting in a -45.18% surprise. Revenue reached 398.00 thousand, compared to an expected 492.32 thousand, with a -19.16% difference. The market reacted with a -14.78% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.35 USD, with revenue projected to reach 720.63 thousand USD, implying an decrease of -58.82% EPS, and increase of 81.06% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
CalciMedica, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$1.30
Actual
-$0.72
Surprise
+44.64%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
FAQ
What were VolitionRx Limited's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, VolitionRx Limited reported EPS of -$0.85, missing estimates by -45.18%, and revenue of $398.00K, -19.16% below expectations.
How did the market react to VolitionRx Limited's Q2 2026 earnings?
The stock price moved down -14.78%, changed from $0.63 before the earnings release to $0.54 the day after.
When is VolitionRx Limited expected to report next?
The next earning report is scheduled for Nov 12, 2026.
What are the forecasts for VolitionRx Limited's next earnings report?
Based on 6
analysts, VolitionRx Limited is expected to report EPS of -$0.35 and revenue of $720.63K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.